Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib,...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA, undervalued on P/FC.
Target Price
The average target price of DAWN is 22 and suggests 83% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell